Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT06323681Not ApplicableRecruiting

Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study）

Role: lead

NCT05671315Not ApplicableRecruiting

A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients

Role: lead

NCT04952207Unknown

Effectiveness and Safety of Direct-Acting Antiviral Agents for the Treatment of Chronic Hepatitis C

Role: lead

NCT04160897Unknown

Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis

Role: lead

All 4 trials loaded